No abstract

No abstract

No abstract

No abstract

1. In order to clarify whether atypical or beta 3-adrenoceptors can modulate canine colonic motility in vivo, we studied the effects of SR 58611A (a selective agonist for atypical beta-adrenoceptors) alone and after pretreatment with beta-adrenoceptor antagonists on colonic motility in the conscious dog. The gastrocolonic response (postprandial increase in motility) was monitored by means of electrodes and strain-gauge force transducers chronically implanted along the distal colon. In some experiments, heart rate was also measured. The possible role of beta 3-adrenoceptors in mediating the effects of SR 58611A was also tested in vitro in circular muscle strips taken from the canine distal colon. 2. Intravenous infusion of SR 58611A, ritodrine or isoprenaline at doses inducing the same degree of tachycardia inhibited the gastrocolonic response to a different extent, with SR 58611A and ritodrine being more effective than isoprenaline. 3. In a dose-response study, SR 58611A was more potent in inhibiting colonic motility than in inducing tachycardia: the ED35 values for inhibition of colonic motility and induction of tachycardia were 23 and 156 micrograms kg-1, i.v., respectively. 4. The inhibitory effect of SR 58611A 100 micrograms kg-1, i.v., on the gastrocolonic response was reversed by alprenolol (non-selective beta-adrenoceptor antagonist), but resistant to CGP 20712A (beta 1-adrenoceptor antagonist) or ICI 118551 (beta 2-adrenoceptor antagonist). 5. In vitro, SR 58611A concentration-dependently relaxed circular muscle strips, an effect that was competitively antagonized by alprenolol with a pA2 value of 7.1, but resistant to CGP 20712A (100 nM), ICI 118551 (100 nM) or tetrodotoxin (1 microM). 6. The present study provides strong functional evidence for a role of atypical or beta 3-adrenoceptors in the modulation of canine colonic motility both in vivo and in vitro by an inhibitory effect most likely at the smooth muscle level.

No abstract

Plant molecules are continuously investigated to prevent and treat in ammatory and ulcerative disorders associated with the gastrointestinal tract, such as gastritis, colitis, mucositis, and ulcer. However, most of the work published is devoted to investigating the therapeutic properties of secondary plant metabolites. This work investigated the gastroprotective activity of a lipid transfer protein isolated from Morinda citrifolia L., named McLTP 1 , when orally administered to mice, from the perspective of its use as a novel peptide-based drug for the prevention and treatment of ulcerative gastric lesions. Pretreatment with McLTP 1 at different doses (4, 8, or 16 mg/kg) reduced ethanol-induced gastric lesions (p < 0.05) in 40%, 84%, and 88%, respectively. In ethanol-induced gastric lesions, it was demonstrated alterations in levels of GSH (↑100%; p < 0.05) and a reduction by 45% in the levels of MDA (p < 0.05) after McLTP 1 administration (8 mg/kg). McLTP 1 showed an anti-in ammatory effect through the modulation of the cytokines IL-10 (↑33%) and TNF-α (↓54%) and was able to reduce MPO levels (↓95%) in the gastric tissue. Besides, the gastroprotective of McLTP 1 also involves the production of nitric oxide. The present ndings reveal that McLTP 1 has a gastroprotective effect dependent, at least in part, on its antiin ammatory and antioxidant effects.

Plant molecules are continuously investigated to prevent and treat inflammatory and ulcerative disorders associated with the gastrointestinal tract, such as gastritis, colitis, mucositis, and ulcer. However, most of the work published is devoted to investigating the therapeutic properties of secondary plant metabolites. This work investigated the gastroprotective activity of a lipid transfer protein isolated from Morinda citrifolia L., named McLTP1, when orally administered to mice, from the perspective of its use as a novel peptide-based drug for the prevention and treatment of ulcerative gastric lesions. Pretreatment with McLTP1 at different doses (4, 8, or 16 mg/kg) reduced ethanol-induced gastric lesions (p < 0.05) in 40%, 84%, and 88%, respectively. In ethanol-induced gastric lesions, it was demonstrated alterations in levels of GSH (↑100%; p < 0.05) and a reduction by 45% in the levels of MDA (p < 0.05) after McLTP1 administration (8 mg/kg). McLTP1 showed an anti-inflammatory effect through the modulation of the cytokines IL- 10 (↑33%) and TNF-α (↓54%) and was able to reduce MPO levels (↓95%) in the gastric tissue. Besides, the gastroprotective of McLTP1 also involves the production of nitric oxide. The present findings reveal that McLTP1 has a gastroprotective effect dependent, at least in part, on its anti-inflammatory and antioxidant effects.